Fish oil
- Generic Name
- Fish oil
- Brand Names
- Omegaven
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- XGF7L72M0F
- Background
Fish oil is a component of SMOFLIPID, which was FDA approved in July 2016. It is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
...
- Indication
Under FDA approval, fish oil pharmaceuticals are typically products consisting of a combination of the omega-3-fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and are indicated primarily as an adjunct to diet to reduce triglyceride levels in adult patients with severe (>=500 mg/dL) hypertriglyceridemia .
...
- Associated Conditions
- -
- Associated Therapies
- Dietary and Nutritional Therapies, Nutritional supplementation, Parenteral Nutrition
Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Medical Center Alkmaar
- Target Recruit Count
- 44
- Registration Number
- NCT02231203
- Locations
- 🇳🇱
Medical Center of Alkmaar, Alkmaar, Noord Holland, Netherlands
Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis
- Conditions
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- University of California, San Diego
- Registration Number
- NCT02148146
- Locations
- 🇺🇸
UC San Diego Medical Center, San Diego, California, United States
🇺🇸Rady Children's Hospital of San Diego, San Diego, California, United States
Effects of Metformin and Fish Oil on Treatment With Clozapine
- Conditions
- Interventions
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Duke University
- Target Recruit Count
- 34
- Registration Number
- NCT02140788
Omegaven Expanded Access Protocol
- First Posted Date
- 2014-04-24
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- St. Luke's Health System, Boise, Idaho
- Registration Number
- NCT02121769
- Locations
- 🇺🇸
St. Luke's Pediatric Gastroenterology, Boise, Idaho, United States
Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury
- Conditions
- Interventions
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Children's Medical Center Dallas
- Target Recruit Count
- 15
- Registration Number
- NCT02010034
- Locations
- 🇺🇸
Children's Medical Center of Dallas, Dallas, Texas, United States
Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients
- Conditions
- Interventions
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 30
- Registration Number
- NCT01999413
- Locations
- 🇫🇷
Emmanuel GYAN, Tours, France
Treatment of Anxiety and Anorexia Nervosa in Adolescents
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Andrea Bonny
- Target Recruit Count
- 24
- Registration Number
- NCT01933243
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- University Hospitals, Leicester
- Target Recruit Count
- 21
- Registration Number
- NCT01870791
- Locations
- 🇬🇧
University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom
Compassionate Use of an Intravenous Fish Oil Emulsion in Infants With Cholestasis
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Arthur J De Lorimier
- Target Recruit Count
- 12
- Registration Number
- NCT01601652
- Locations
- 🇺🇸
University of California Davis Medical Center, Sacramento, California, United States
A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT01594983
- Locations
- 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.